Santaris Pharma and miRagen Therapeutics have extended their worldwide strategic alliance to discover and develop LNA-drugs targeting disease causing microRNAs.

Under the extended agreement miRagen gains an extensive non-exclusive license in the miRNA therapeutics field for therapeutics research and global rights to develop and commercialise LNA drugs against six additional microRNA targets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the addition of these targets, which concern human disease areas of high unmet need, the total number of targets under the agreement reaches ten.

"Under the extended agreement miRagen gains an extensive non-exclusive license in the miRNA therapeutics field for therapeutics research and global rights to develop and commercialise LNA drugs against six additional microRNA targets."

Santaris Pharma business development CSO and VP Henrik Ørum said the collaboration with miRagen is an important part of the company’s corporate strategy in the microRNA therapeutics field.

"MicroRNA therapy is an exciting new branch of human medicine where the LNA drug platform has already provided proof-of-concept in Phase II clinical studies in HCV patient using Santaris´miRNA-122 inhibitor, Miravirsen," Ørum said.

See Also:

As a part of the deal, Santaris will earn a combination of cash and equity for the licenses, in addition to clinical milestones and royalties on products resulting from the alliance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Financial terms of the transaction were not revealed.

miRagen president and CEO William Marshall said the partnership with Santaris has been very productive.

"Our goal is to identify important disease causing microRNAs and to deploy the world’s best technologies to create therapeutic development candidates against diseases with high unmet medical need," Marshall said.